HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Corcept Therapeutics (NASDAQ: CORT) and maintained a price target of $165 for the stock.